tapebrief
IDXX · Q2 2025

IDXX · Q3 2025 Earnings

Bullish

Idexx Laboratories

Reported November 3, 2025

30-second summary

30-second take: Q3 revenue of $1.105B grew 13.3% YoY (CAG Diagnostics recurring +11.5%, 10% organic) and non-GAAP EPS hit $3.22 with operating margin expanding 100bps reported / 120bps comparable. Idexx raised every FY2025 guide for the second consecutive quarter — revenue midpoint +$42.5M to $4.285B, EPS midpoint +$0.33 to $12.91, and the inVue Dx placement target moves from 5,500 to ~6,000 (originally 4,500 entering the year). With over 1,700 placements in Q3 and U.S. CAG recurring growth premium to clinical visits now at ~950bps, the frequency-expansion thesis is compounding faster than even the August raise implied.

Headline numbers

EPS

Q3 FY2025

$3.22

Revenue

Q3 FY2025

$1.10B

+13.3% YoY

Gross margin

Q3 FY2025

61.8%

Free cash flow

Q3 FY2025

$0.37B

Operating margin

Q3 FY2025

32.1%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$1.10B+13.3%$1.11B-0.4%
EPS$3.22—$3.50-8.0%
Gross margin61.8%—62.6%-80bps
Operating margin32.1%—33.6%-150bps
Free cash flow$0.37B—$0.15B+144.1%

Guidance

IDEXX raises full-year FY2025 guidance across revenue, EPS, margins, and innovation metrics, with significant increases in CAG Diagnostics growth outlook and IDEXX inVue Dx deployment expectations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2025
$4,205M - $4,280M$4,270M - $4,300M+$65M - $20M (midpoint +$32.5M)Raised
Reported revenue growth
FY2025
7.7% - 9.7%9.6% - 10.3%+1.9 to +0.6 percentage pointsRaised
Organic revenue growth
FY2025
7.0% - 9.0%8.8% - 9.5%+1.8 to +0.5 percentage pointsRaised
CAG Diagnostics recurring revenue reported growth
FY2025
6.5% - 8.7%8.3% - 9.0%+1.8 to +0.3 percentage pointsRaised
CAG Diagnostics recurring revenue organic growth
FY2025
5.8% - 8.0%7.5% - 8.2%+1.7 to +0.2 percentage pointsRaised
EPS (GAAP)
FY2025
$12.40 - $12.76$12.81 - $13.01+$0.41 to +$0.25 (midpoint +$0.33)Raised
Reported EPS growth
FY2025
16% - 20%20% - 22%+4.0 to +2.0 percentage pointsRaised
Comparable EPS growth
FY2025
9% - 13%12% - 14%+3.0 to +1.0 percentage pointsRaised
Operating margin (reported)
FY2025
31.3% - 31.6%31.6% - 31.8%+30 to +20 basis pointsRaised
IDEXX inVue Dx placements
FY2025
5,500 placementsapproximately 6,000 placements+500 placements (+9.1%)Raised
IDEXX inVue Dx instrument revenues
FY2025
over $60 millionover $65 million+$5M+ (+8.3%+)Raised

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Companion Animal Group (CAG)$1.013B+13.5%
Water$0.054B+8.2%
Livestock, Poultry and Dairy (LPD)$0.034B+17.1%
CAG Diagnostics recurring revenue$0.873B+11.5%
IDEXX VetLab consumables$0.388B+17.8%
CAG Diagnostics capital instruments$0.051B+74.3%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
United States revenue$0.705B+10.5%
International revenue$0.4B+18.6%
CAG Diagnostics recurring revenue organic growth10% organic—
IDEXX inVue Dx placementsOver 1,700 placements in Q3—
Premium instrument installed base growth10% global growth—
Operating margin expansion (reported)100 basis points YoY—
Operating margin expansion (comparable)120 basis points YoY—
Free cash flow conversionTrailing twelve months 107% of net income—
CAG Diagnostics International organic growth14% organic—
EPS comparable growth15% comparable basis—

Management tone

Narrative arc: Q2 (inVue Dx ramp acceleration) → Q3 (inVue Dx as "one of the most successful product rollouts in IDEXX history").

Three months ago, management treated inVue Dx as a high-confidence ramp story with a fresh placement raise from 4,500 to 5,500. This quarter the language hardened to superlatives: "This represents one of the most successful product rollouts in IDEX's history." Raising again to ~6,000 — having entered 2025 at 4,500 — signals management believes the constraint is execution capacity, not demand. The Q4 implied run-rate of 1,500–1,600 placements (per the Stifel exchange) puts inVue Dx into a recurring-revenue compounding regime that will dominate the 2026 setup.

Last quarter, U.S. clinical visits at -2.5% were the "constant against which the diagnostic frequency story plays out." This quarter that frame became quantified and weaponized: management cited "IDEX U.S. CAG Diagnostics recurring revenue growth premium to U.S. clinical visits of approximately 950 basis points" — wider than Q2's ~800bps premium and a direct rebuttal to the wellness-visit-decline narrative. Non-wellness visits were near flat in Q3 while wellness declined 2.5%, and management is leaning into the aging-pet (5+ years) demographic as a structural driver of diagnostic frequency per visit.

CancerDx has moved from "emerging oncology offering" two quarters ago to a multi-indication, internationally-launching franchise. Management announced "we will further expand our cancer DX franchise in 2026 with the addition of mast cell tumor and another high-impact cancer biomarker" plus international rollout starting Q1 2026. With ~5,000 ordering practices now (vs. 2,500 in Q2), the test has roughly doubled penetration in one quarter and the company is signaling the screening use case (dogs 7+) will eventually exceed the current aid-in-diagnosis use case.

The international growth story shifted from "runway" to "operating leverage in flight." Management framed international CAG Dx recurring growth of 14% organic as the output of "four-to-five years of sales force expansion" and reference lab buildout that's now maturing — and reiterated international growth should run 200+bps faster than the U.S. long-term. Eleven consecutive quarters of double-digit international installed-base growth is no longer being introduced; it's being compounded on.

Catalyst Cortisol, launched at the end of Q2, was already cited this quarter with "over a quarter of Catalyst customers in North America adopting the test within the first three months of launch" — among the fastest manual menu expansions in Catalyst history. Management is now treating the Catalyst platform itself as a serial menu-launch vehicle rather than a stable installed-base asset.

Recurring themes management leaned on this quarter:

Innovation driving disproportionate growth premium over market conditionsGlobal commercial execution translating to 11 consecutive quarters of double-digit international installed base growthDiagnostics frequency and utilization per visit as sustainable competitive moatCloud-based SaaS vertical integration strengthening customer stickinessSuccessful product launches (InViewDX, CancerDX, Catalyst Cortisol) creating multi-year recurring revenue streamsPricing power and net price realization offsetting macro softness

Risks management surfaced:

U.S. same-store clinical visits continuing to decline, though at moderately better rates than year-to-date averageOngoing macro and sector pressures impacting U.S. veterinary clinic visit volumesForeign exchange headwinds to reported revenue growthPotential tariff impacts from trade landscape changes, though mitigated by U.S.-based manufacturing footprintShift of pancreatic lipase testing from rapid assay to Catalyst platform creating internal cannibalization headwind

Q&A highlights

Erin Wright · Morgan Stanley

How much of the consumables strength is driven by in-view placements versus broad-based installed base growth? What metrics track the economic value contribution of new placements?

Management emphasized broad-based growth driven by 10% installed base expansion, new specialty tests (lipase, SmartQC, cortisol), and early-stage in-view adoption. In-view is all incremental, proceeding well to plan, and expected to contribute greater amounts forward. Most in-view customers expected to adopt FNA testing alongside existing tests.

Large installed base growth of 10%Three new specialty tests launched within one yearIn-view is all incremental (did not exist before)Vast majority of in-view customers expected to use FNA tests in addition to cytology and blood morphology

Michael Riskin · Bank of America

How is the company parsing out strength across in-view rollout, consumables uplift, and lab diagnostics despite end-market weakness? What is the cross-selling leverage opportunity and impact on IDEXX premium pricing?

Management attributed performance to non-wellness visits near flat in Q3, aging pet population (5+ years) driving higher clinical visits, and expanded diagnostic frequency. Wellness visits declined 2.5%. In-view has both direct capital benefits and indirect benefits through IDEXX 360 marketing programs, driving reference lab and rapid assay cross-sell. Two-thirds of in-view placements in North America, one-third international.

Non-wellness visits near flat in Q3Wellness visits declined 2.5%Aging pets driving higher diagnostic frequency and visit qualityTwo-thirds of in-view placements in North America, one-third international

John Block · Stifel

Does the 1,500 system placement guidance for Q4 2025 suggest order fulfillment is caught up? What are thoughts on the original 20,000 over five-year goal given strong year-one performance?

Management reaffirmed 6,000 placements targeted by end of 2025 (well above initial 4,500 guidance), representing strong year-one demand. 1,500 to 1,600 placements implied for Q4 is solid trajectory. Original 20,000 over five years goal unchanged; company still focused on that target and feels good about trajectory given FNA extensibility.

6,000 total in-view placements targeted by end of 2025Up from initial guidance of 4,500 at year startImplied Q4 2025 placements: 1,500 to 1,600 systemsOriginal 20,000 placements over five years unchanged

John Block · Stifel

International CAG diagnostic recurring revenue grew 14% (highest since COVID), with limited in-view and CancerDx contribution. What is driving this strength and is it the right run rate given tailwinds from innovation and sales rep expansion?

Management attributed growth to embryonic diagnostics adoption in international markets, four-to-five years of sales force expansion, maturing commercial ecosystem (account managers, VDC, field service, inside sales), reference lab network buildout, and software localization. About 100 basis points of benefit came from equivalent days adjustment. Management guided international growth 200+ basis points faster than U.S. long-term.

International CAG diagnostic recurring revenue up 14% (highest post-COVID)About 100 basis points of benefit from equivalent days adjustmentFour-to-five years of sales force expansion ongoingInternational opportunity guided at 200+ basis points faster than U.S.

Andrea Alfonso · UBS

On CancerDx, what age/frequency guidelines are practices adopting for screening? How is the company engaging on wellness visit initiation given wellness visit declines?

Two use cases: aid in diagnosis (dogs with clinical symptoms, currently majority) and wellness screening (dogs 7+ years or specific high-risk breeds). Management expects screening to become majority use case over time. Panel expansion (lymphoma plus mast cell tumor = over one-third of cancer cases) improves screening value proposition. Third cancer screen planned for 2026 to achieve menu comprehensiveness for wellness adoption.

CancerDx screening recommended for dogs 7+ years and high-risk breedsLymphoma plus mast cell tumor represents over one-third of cancer cases in dogsThird cancer screen planned for 2026Currently majority of use is aid in diagnosis; expected to flip to screening majority

Answers to last quarter's watch list

inVue Dx placement cadence. Resolved positively. Q3 delivered >1,700 placements; FY target raised from 5,500 to ~6,000, implying ~1,500–1,600 in Q4 (per the Stifel exchange). Cumulative placements through Q3 are tracking ~4,400 of the new 6,000 target — well clear of the original 4,500 FY plan entering the year. Status: Resolved positively
U.S. CAG Diagnostics recurring revenue growth re-acceleration. Resolved positively. The U.S. CAG recurring growth premium to clinical visits expanded to ~950bps in Q3 from ~800bps in Q2, with U.S. revenue growth of 10.5%. The frequency-expansion thesis is proving out: management explicitly cited 9.5% revenue growth against 1.2% visit decline as the share/wallet-gain evidence. Status: Resolved positively
Q3 comparable operating margin direction. Resolved positively. Q3 reported operating margin expanded 100bps YoY and comparable margin expanded 120bps YoY — well above the Q2 framing of "modest" comparable expansion. The FY operating margin guide was raised to 31.6–31.8%, with FY non-GAAP operating margin landing at 31.7%. Status: Resolved positively
CancerDx pull-through to reference lab volumes. Continue monitoring. Ordering practices roughly doubled to ~5,000 from 2,500 in Q2, and the international launch is teed up for Q1 2026 with two new biomarkers. Direct reference lab segment growth wasn't itemized in the print, but the international panel expansion and mast cell tumor addition are the catalysts to watch in 2026. Status: Continue monitoring
VetLab consumables organic growth sustainability. Resolved positively. Q3 VetLab consumables grew 17.8% — accelerating from Q2's 13.6% organic and well clear of the "sustain double digits" bar. The inVue Dx + installed-base + new specialty test trio is compounding faster than the Q2 setup suggested. Status: Resolved positively

What to watch into next quarter

Q4 inVue Dx placement landing point. The new ~6,000 FY target implies 1,500–1,600 in Q4 vs. >1,700 in Q3. Watch whether placements stay above 1,500 (validating the demand-not-supply constraint thesis) or step down materially (which would suggest the Q3 surge consumed pipeline).

2026 placement framing. Management reaffirmed the 20,000 five-year goal but hasn't yet sized 2026. With ~6,000 in 2025, a flat-to-up 2026 placement guide would be the bull case; anything below ~5,000 would imply the original 5-year plan is the ceiling, not a floor.

CancerDx international launch contribution. The Q1 2026 international rollout plus mast cell tumor and a third biomarker need to translate into a visible step-up in reference lab services growth. Watch whether reference lab growth re-accelerates above Q2's 5.9% in Q4 and Q1 2026 commentary.

U.S. CAG Dx recurring growth premium to visits. Premium widened from ~800bps to ~950bps in one quarter. If it holds above 900bps with clinical visits still negative, the structural-frequency thesis is locked in for 2026 modeling.

FY2026 margin framing. FY2025 lands at 31.7% operating margin (comparable +120bps Q3). Watch whether the FY2026 initial guide signals continued 50–100bps expansion or whether commercial investments (sales force, international country builds, R&D) consume the leverage.

Catalyst Cortisol pull-through. Over 25% of North American Catalyst customers adopted within three months. Watch whether the Q4 print shows Catalyst consumables stepping up from the +17.8% Q3 VetLab pace or whether early adoption normalizes.

Sources

  1. IDXX Q3 2025 press release, SEC filing (Form 8-K Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/874716/000110465925105185/tm2530045d1_ex99-1.htm
  2. IDXX Q3 2025 earnings conference call (Q&A and prepared remarks excerpts as captured in extraction)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.